LAG3 and melanoma: Clinical evidence from the RELATIVITY-047 trial in melanoma has validated the therapeutic synergy between LAG-3 and PD-1 inhibition, as combining relatlimab (anti-LAG-3) with nivolumab improved outcomes over PD-1 monotherapy, leading to FDA approval in melanoma [162].